vTv Therapeutics Inc. financial data

Symbol
VTVT on Nasdaq
Location
3980 Premier Dr, Suite 310, High Point, NC
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 784 % +68.2%
Debt-to-equity 107 % -72.9%
Return On Equity -97.6 % +47.1%
Return On Assets -47.8 % -1.16%
Operating Margin -175K % -7209%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 23.2M USD +1.14%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 17K USD -98.3%
Research and Development Expense 16.2M USD +41.4%
General and Administrative Expense 13.6M USD +0.74%
Operating Income (Loss) -29.8M USD -24.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -28.4M USD -25.5%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -23.5M USD -28.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 98.5M USD +137%
Accounts Receivable, after Allowance for Credit Loss, Current 62K USD -39.2%
Other Assets, Current 112K USD
Assets, Current 99.5M USD +132%
Property, Plant and Equipment, Net 14K USD -72%
Operating Lease, Right-of-Use Asset 24K USD -84.6%
Assets 99.5M USD +131%
Accounts Payable, Current 939K USD -77%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 10.2M USD +58.2%
Contract with Customer, Liability, Noncurrent 18.7M USD 0%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 29M USD +14.7%
Retained Earnings (Accumulated Deficit) -320M USD -7.93%
Stockholders' Equity Attributable to Parent 70.5M USD +370%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 70.5M USD +294%
Liabilities and Equity 99.5M USD +131%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.69M USD +22.5%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.69M USD -113%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 98.5M USD +137%
Deferred Tax Assets, Valuation Allowance 34M USD +17.2%
Deferred Tax Assets, Gross 34M USD +17.2%
Operating Lease, Liability 125K USD -58.1%
Depreciation 9K USD -59.1%
Lessee, Operating Lease, Liability, to be Paid 129K USD -59.9%
Property, Plant and Equipment, Gross 536K USD -11.3%
Operating Lease, Liability, Current 32K USD -82.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8K USD -75.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 27.8M USD +17.3%
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 3.58M USD +53.1%
Interest Expense 13K USD -13.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares